Voice of Regenerative Medicine : CIRM Embezzle $32 million CA Stem Cell Research Fund to Bank Fake Science in UC and Out of State

Friday, April 12, 2013

CIRM Embezzle $32 million CA Stem Cell Research Fund to Bank Fake Science in UC and Out of State

CIRM (California Institute for Regenerative Medicine) withhold Prop 71 from CA human embryonic stem cell (hESC) research and facility, such as our grant applications targeting for heart and neurological diseases in accordance with Prop 71 pursuant to Prop 71 and consistent with Prop 71 (e.g., TR4-06762; DR2-05339; TR3-05505; RB4-06272). San Diego Regenerative Medicine Institute (SDRMI) hESC neuronal & cardiomyocyte therapy derivatives are the only human cell sources with adequate capacity to regenerate neurons & contractile heart muscles, vital for CNS and heart repair in the clinical setting. Recent advances and breakthroughs in SDRMI hESC research have overcome some major obstacles in bringing hESC therapy derivatives towards clinical applications. SDRMI & Xcelthera have established human stem cell technology platforms for defined culture systems for derivation and maintenance of clinical-grade pluripotent hESCs (PluriXcel-DCS) and lineage-specific differentiation of pluripotent hESCs by small molecule induction for direct conversion of pluripotent hESCs into neuronal cells or heart muscle cells for developing safe and effective stem cell therapies (PluriXcel-SMI). Such milestone advances and medical innovations in SDRMI & Xcelthera hESC research enable generation of a large supply of high purity clinical-grade hESC neuronal (Xcel-hNuP & Xcel-hNu) & heart (Xcel-hCardP & Xcel-hCM) cell therapy products for treating neurological & heart diseases & injuries. Please go to our websites at http://www.sdrmi.org & http://www.xcelthera.com to see SDRMI & Xcelthera stem cell research breakthrough publications, human stem cell therapy products and technology platforms, and watch videos of hESC heart beats (hESC-derived heart muscle cells) & slideshow of evolution of CNS neuron cells from hESCs by SDRMI & Xcelthera exclusive human stem cell technique PluriXcel-SMI.

On the other hand, CIRM embezzle CA stem cell research fund to conflict of interest in UC and out of state to waste on banking stem cell frauds and scams. Abnormal iPS cells are made from adult skin cells and disease tissues have nothing to do with stem cell research of Prop 71. Anyone in his/her right state of mind would believe such ridiculous fake science that disease tissues would make any stem cells as CIRM press release claimed, which would make CIRM communication officer Kevin McCormack of no moral integrity sound very much like a stem cell con man. Why would CIRM waste ~$32 million taxpayers’ money to have those UC and out of state researchers to collect disease tissues and bank disease cells? CIRM gave $10 M CA bond to Coriell Institute for Medical Research & $16 M more CA bond to Cellular Dynamics International of Jamie Thomson, both company are outside of California. Is it obvious that the only reason they got the multi-millions of awards from California stem cell agency is their connection with somebody on CIRM board, such as CIRM chair Jon Thomas & top officials with these out state company Florida WSCS meeting & NIH director personalized medicine & iPS center director Dr. Rao for banking into CIRM Buck Institute resources. While other CIRM resources so far have been withholding California stem cell research resources & infrastructure built with > $300 millions of state fund, such as Sanford Consortium for Regenerative Medicine & UC Stem Cell Centers, from stem cell research, turning those expensive state stem cell center buildings into few UC professors’ penthouses, visibly vacant of any stem cell research, no recruiting or collaborating or sharing activities with any stem cell research expertise who have demonstrated achievement in the area of pluripotent stem cell & progenitor cell biology & medicine according to Prop 71, wasting state fund and resources enormously.

No comments:

Post a Comment

Public Interest

The successful derivation of human embryonic stem cell (human ES cell) lines from the in vitro fertilization (IVF) leftover embryos is considered as one of the major breakthroughs of the life sciences. The pluripotent human ES cells, derived from the inner cell mass (ICM) or epiblast of human blastocyst or human embryos, have both the unconstrained capacity for long-term stable undifferentiated growth in culture and the intrinsic potential for differentiation into all somatic cell types in the human body, holding tremendous potential for human tissue and function restoration. Therefore, human ES cells have been regarded as an ideal source to provide an unlimited supply of large-scale well-characterized human specialized cell types for cell-based therapies to resolve some worldwide major health problems, such as neurodegenerative diseases, paralysis, diabetes, and heart diseases. A small portion of the millions of excess embryos currently stored in the IVF clinics worldwide, which are otherwise destined for destruction, could potentially be an unlimited source to deliver in the future a whole range of therapeutic treatments for tissue and function restoration in patients with life-threatening diseases and injuries. However, human ES cell research has generated intense public interest as well as controversy due to concerns of products of human ES cell cultures that can only be obtained by the use, involving their destruction, of human embryos. The recent years’ court battles on Federal funding for human ES cell research in the United State (US) as well as the patentability of US and international patents directed to human ES cell technologies have also highlighted the decade long ethical, moral, social, and legal controversy surrounding the public interest of human ES cells involving destruction, commercial or industrial uses of human embryos. As neurodegenerative and heart diseases incur exorbitant costs on the healthcare system worldwide, there is a strong focus on providing newer and more efficient solutions for these therapeutic needs. Millions of people are pinning their hopes on human ES cell research. California voters have passed Proposition 71 to designate $3B public fund to support pluripotent human ES cell research and therapy development for the benefit of public health. In spite of ethical debates surrounding the ownership and funding issues of human ES cells, in the case of many incurable or hitherto untreatable life-threatening or devastating diseases, supporting human ES cell research is crucial to driving the advance of medicine to provide optimal regeneration and reconstruction treatment options to improve the function, wellness, and overall quality of life. To answer the intense public interest surrounding human ES cell research and enormous public healthcare benefits thereof, Voice of Regenerative Medicine provides a ground of public debate or voice or blog for the controversies surrounding public interest of human ES cells centering on scientific, economic, ethical, moral, social, financial conflict of interest, and legal issues, to increase public awareness and understanding of the scientific advancement of human ES cell research, and of the importance, urgency, and tangible benefits of human ES cell-based regenerative medicine to improving the function, wellness, and overall quality of life for patients suffering from incurable or hitherto untreatable life-threatening or devastating diseases; to increase public support for human ES cell research; to improve policy making and funding situation for human ES cell research, and to identify and disclose publicly those scientific, economic, ethical, moral, social, financial conflict of interest, and legal issues that have impeded the progress of human ES cell research and stem cell therapy development, introduction of medical innovations and new business opportunities based on human ES cell research, and bringing new therapeutics into the market.

Disclaimer:

This “Voice of Regenerative Medicine” blog is to provide a public voice and an open forum to human embryonic stem cell research and regenerative medicine start-up. All content provided on this blog is for informational purposes only. This blog makes no representations as to accuracy, completeness, correctness, reliability, suitability, or validity of any information on this site or found by following any link on this site, and will not be liable for any errors or omissions or availability in this information, or any losses, injuries, or damages arising from the display or use of this information. The inclusion of any content, images, documents, files, and links on the blog does not necessarily imply a recommendation or endorse the views expressed within them. The content of any postings or comments on the blog do not necessary reflect or do not necessary represent the positions, strategies, views, or opinions of the owners, authors, bloggers, or San Diego Regenerative Medicine Institute or any organizations or any companies or any director, officer, or employee thereof. This blog is not associated with, affiliated with, a partner with, belonging to, or acting upon any organizations or individuals. The blog’s content is not generated to make money or paid for blogging content. It is natural for the content on the blog to be controversial or contentious. The content on the blog is the opinion only, not intended to malign any religion, ethnic group, club, organization, company, or individual, or anyone or anything. The owners, bloggers, San Diego Regenerative Medicine Institute, any individuals, any organizations, and any companies are not responsible, nor will be held liable, for the content or comments or the display or use of any information on the blog. Our intention is to do no harm, to not injure others, defame, or libel. All information is provided on an as-is basis. These terms and conditions are subject to change at anytime and without notice.